Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $370 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $370.
October 16, 2023 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $370.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Vertex Pharmaceuticals. The maintained price target of $370 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100